Axillary surgery versus no-axillary staging in T1N0 breast cancer: 20-year follow-up of the INT 09/98 randomized clinical trial

象限切除术 医学 乳腺癌 危险系数 腋窝淋巴结 腋窝 外科 临床终点 随机对照试验 前哨淋巴结 乳房切除术 肿瘤科 癌症 内科学 置信区间
作者
Roberto Agresti,Marco Sandri,Giuseppe Capri,Giulia Bianchi,Tiziana Triulzi,Laura Lozza,Giovanna Trecate,A Trapani,Cristina Ferraris,Biagio Paolini,Sylvie Ménard,Marco Greco,Secondo Folli,Elda Tagliabue
出处
期刊:British Journal of Surgery [Oxford University Press]
卷期号:112 (3) 被引量:1
标识
DOI:10.1093/bjs/znae311
摘要

The role of axillary surgery in breast cancer has shifted over time from a therapeutic operation to a staging method for subsequent adjuvant therapies, through the introduction of sentinel lymph node biopsy. The discovery of molecular subtypes has since questioned the necessity of axillary staging in breast cancer. The INT09/98 randomized trial explored the omission of axillary surgery in early-stage breast cancer in patients under 65 years of age. From June 1998 to June 2003, a total of 565 T1N0 breast cancer patients were enrolled. The trial tested the non-inferiority of quadrantectomy without axillary surgery (QU) compared to quadrantectomy with axillary dissection (QUAD). The primary endpoint was overall survival (OS). Secondary endpoints included disease-free survival (DFS) and incidence/timing of axillary lymph node metastasis in the QU arm. Follow-up at 20 years showed no significant differences between the QU versus the QUAD arm. The adjusted hazard ratio for OS was 1.18 (P = 0.326) and DFS was 1.27 (P = 0.280) respectively, both within the predetermined non-inferiority limit. Axillary relapse rates in the QU arm remained low, indicating that only a subset of metastatic nodes cause recurrences if not removed. In the QU arm, patients with favourable biological features but unknown axillary node involvement did not receive adjuvant chemotherapy, without significant differences in outcomes. The axillary relapse rate with distant metastases was similar in both arms and may reflect aggressive biology of the primary tumour. Avoiding axillary surgery and reducing adjuvant treatments in early breast cancer does not increase distant metastases or affect long-term survival. Axillary relapsed patients with distant metastases in both QU and QUAD arms may represent cancers with genomically determined poorer prognosis, independent of surgical intervention and adjuvant therapies. NCT01508546 (http://www.clinicaltrials.gov).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
上官若男应助Estrange采纳,获得10
1秒前
wanci应助ZYQ采纳,获得30
1秒前
3秒前
天天快乐应助大胆的向松采纳,获得10
3秒前
3秒前
脑洞疼应助乔木自燃采纳,获得10
4秒前
marco完成签到,获得积分10
5秒前
搞原创的小白完成签到,获得积分10
5秒前
张雯雯完成签到,获得积分10
6秒前
leaves发布了新的文献求助10
7秒前
dandna完成签到 ,获得积分10
7秒前
7秒前
一一发布了新的文献求助10
7秒前
8秒前
9秒前
云云完成签到,获得积分10
9秒前
riverhejiang发布了新的文献求助10
11秒前
11秒前
12秒前
12秒前
honphyjiang完成签到,获得积分10
13秒前
TaoYe完成签到,获得积分10
13秒前
aikey完成签到 ,获得积分10
14秒前
俊秀的芫发布了新的文献求助10
14秒前
shea发布了新的文献求助10
14秒前
yuan完成签到 ,获得积分10
17秒前
大胆的向松完成签到,获得积分20
18秒前
寒江雪发布了新的文献求助10
18秒前
量子星尘发布了新的文献求助10
20秒前
李健应助GehaoZhang采纳,获得10
20秒前
21秒前
HAN发布了新的文献求助10
21秒前
22秒前
辛卫铎完成签到,获得积分10
22秒前
王肄博完成签到 ,获得积分10
22秒前
22秒前
回忆永恒完成签到,获得积分10
22秒前
行天华完成签到,获得积分10
22秒前
23秒前
乔木自燃发布了新的文献求助10
26秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Acute Mountain Sickness 2000
Handbook of Milkfat Fractionation Technology and Application, by Kerry E. Kaylegian and Robert C. Lindsay, AOCS Press, 1995 1000
A novel angiographic index for predicting the efficacy of drug-coated balloons in small vessels 500
Textbook of Neonatal Resuscitation ® 500
The Affinity Designer Manual - Version 2: A Step-by-Step Beginner's Guide 500
Affinity Designer Essentials: A Complete Guide to Vector Art: Your Ultimate Handbook for High-Quality Vector Graphics 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 5069824
求助须知:如何正确求助?哪些是违规求助? 4291039
关于积分的说明 13369363
捐赠科研通 4111305
什么是DOI,文献DOI怎么找? 2251392
邀请新用户注册赠送积分活动 1256574
关于科研通互助平台的介绍 1189116